Form 4: Mineralys Therapeutics Executive Sells Shares
Insider Transaction (Form 4)
David Malcom Rodman, Chief Medical Officer of Mineralys Therapeutics, Inc., sold 20,407 shares of common stock on July 13, 2026.
Summary
- Option exercise/conversion: acquired 3,542 Common Stock at $10.20 ($36,128) on July 13, 2026; holds 61,275 after (Direct).
- Option exercise/conversion: acquired 4,167 Common Stock at $14.25 ($59,380) on July 13, 2026; holds 65,442 after (Direct).
- Option exercise/conversion: acquired 6,349 Common Stock at $1.08 ($6,857) on July 13, 2026; holds 71,791 after (Direct).
- Open-market sale: disposed of 14,058 Common Stock at $27.58 ($387,717) on July 13, 2026; holds 57,733 after (Direct).
- Open-market sale: disposed of 6,349 Common Stock at $26.61 ($168,955) on July 15, 2026; holds 51,384 after (Direct).
- Option exercise/conversion: disposed of 3,542 Stock Option on July 13, 2026; holds 109,792 after (Direct).
- Option exercise/conversion: disposed of 4,167 Stock Option on July 13, 2026; holds 79,167 after (Direct).
- Option exercise/conversion: disposed of 6,349 Stock Option on July 13, 2026 (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $556,671 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
David Malcom Rodman — Officer (Chief Medical Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-13 | Option exercise/conversion | Common Stock | 3,542 | $10 | $36.1K | 61,275 |
| 2026-07-13 | Option exercise/conversion | Common Stock | 4,167 | $14 | $59.4K | 65,442 |
| 2026-07-13 | Option exercise/conversion | Common Stock | 6,349 | $1 | $6.9K | 71,791 |
| 2026-07-13 | Open-market sale | Common Stock | 14,058 | $28 | $387.7K | 57,733 |
| 2026-07-15 | Open-market sale | Common Stock | 6,349 | $27 | $169.0K | 51,384 |
| 2026-07-13 | Option exercise/conversion | Stock Option | 3,542 | — | — | 109,792 |
| 2026-07-13 | Option exercise/conversion | Stock Option | 4,167 | — | — | 79,167 |
| 2026-07-13 | Option exercise/conversion | Stock Option | 6,349 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-13 | Option exercise/conversion (3,542 shares) |
| 2026-07-13 | Option exercise/conversion (4,167 shares) |
| 2026-07-13 | Option exercise/conversion (6,349 shares) |
| 2026-07-13 | Open-market sale (14,058 shares) |
| 2026-07-15 | Open-market sale (6,349 shares) |
| 2026-07-13 | Option exercise/conversion (3,542 shares) |
| 2026-07-13 | Option exercise/conversion (4,167 shares) |
| 2026-07-13 | Option exercise/conversion (6,349 shares) |
Keywords
insider transaction, Form 4, MLYS, Mineralys Therapeutics, Inc., bearish, David Malcom Rodman
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.